This is a preview of subscription content, log in via an institution to check access.
REFERENCES
Cobden I, Record CO, White RWB: Fatal intrahepatic cholestasis associated with triazolam. Postgrad Med J 57:730–731, 1981
Lee MG, Hanchard B, Williams NP: Drug-induced acute liver disease. Postgrad Med J 65:367–370, 1989
Kanda T, Yokosuka O, Ehata T, Maru Y, Imazeki F, Saisho H, Shiratori Y, Omata M: Detection of GBV-C RNA in patients with non-A–E fulminant hepatitis by reversetranscription polymerase chain reaction. Hepatology 25:1261–1265, 1997
Caron GA, Sarkany I: Lymphoblast transformation in sulfonamide sensitivity. Br J Dermatol 77:556–560, 1965
Mizoguchi Y, Yamada T, Monna T, Yamamoto S, Morisawa S: Detection of hypersensitivity to drugs by lymphocyte cultures in drug-induced allergic hepatitis. Gastroenterol Jpn 10:300–306, 1975
Kato Y, Kobayashi K, Hattori N, Takeuchi J, Ohta G: Peripheral lymphocyte culture in the diagnosis of drug induced liver injury. Gastroenterol Jpn 14:216–225, 1979
Yoshiba M, Sekiyama K, Iwamura Y, Sugata F: Development of reliable artificial liver support (ALS)/plasma exchange in combination with hemodiafiltration using high-performance membranes. Dig Dis Sci 38:469–476, 1993
Ichida T, Matsunami H, Kawasaki S, Makuuchi M, Harada T, Ito S Asakura H: Living related-donor liver transplantation from adult to adult for primary biliary cirrhosis. Ann Intern Med 122:275–276, 1995
O'Grady JG, Schalman SW, Williams R: Acute liver failure: redefining the syndromes. Lancet 324:273–275, 1993
Takahashi Y, Shimizu M: Actiology and prognosis of fulminant viral hepatitis in Japan: A multicentre study. The Study Group of Fulminant Hepatitis. J Gastroenterol Hepatol 6:159–164, 1991
Evans WE, Relling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487–491, 1999
Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI: Sensitivity to triazolam in the elderly. N Engl J Med 324:1691–1698, 1991
Bakti G, Fisch HU, Karlaganis G, Minder C, Bricher J: Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: Model experiments with triazolam. Hepatology 7:629–638, 1987
Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89–96, 1989
Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ: Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618–628, 2000
Hunt CM, Westerkam WR, Stave GM: Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 51:275–283, 1992
Schou JS: Triazolam: Adverse effects in relation to dosage. Pharmacol Toxicol 64:6–8, 1989
Felix CA, Walker AH, Lange BJ, Williams TN, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair LA: Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 95:13176–13181, 1998
Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR: CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1 B5′-promoter region polymorphism. Clin Pharmacol Ther 68:82–91, 2000
Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M: Inter individual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201–205, 1999
Japan Pharmaceutical Information Center. Drugs in Japan, 23rd ed. Tokyo; Yakugyojiho Co., Ltd., 2000, pp 1268–1270 (in Japanese)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kanda, T., Yokosuka, O., Fujiwara, K. et al. CASE REPORT: Fulminant Hepatic Failure Associated with Triazolam. Dig Dis Sci 47, 1111–1114 (2002). https://doi.org/10.1023/A:1015054510949
Issue Date:
DOI: https://doi.org/10.1023/A:1015054510949